Table 3 Clinician-reported health information
Total (N = 15) n (%) | |
|---|---|
Menopausal status | |
Pre-menopausal | 3 (20.0%) |
Not on gonadotropin-releasing hormone (GnRH) agonist treatment | 3 (100.0%) |
Post-menopausal | 12 (80.0%) |
Mammalian target of rapamycin (mTOR) inhibitor treatment | |
Yes | 3 (20.0%) |
No | 12 (80.0%) |
Recurrent or progressive disease refractory to non-steroidal aromatase inhibitor (NSAI), tamoxifen, or fulvestrant | |
Yes | 6 (40.0%) |
No | 9 (60.0%) |
Eastern Cooperative Oncology Group (ECOG) score | |
0 | 1 (6.7%) |
1 | 11 (73.3%) |
2 | 3 (20.0%) |
Cyclin-dependent kinase (CDK4/6) inhibitor treatment | |
Yes | 5 (33.3%) |
No | 10 (66.7%) |
Metastatic sitea | |
Bone | 13 (86.7%) |
Lung | 2 (13.3%) |
Liver | 3 (20.0%) |
Lymph node | 1 (6.7%) |
Skin | 1 (6.7%) |